Inactive Instrument
Anacor Pharmaceuticals Inc Stock
Stocks
US0324201013
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 16-05-26 | Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing | RE |
| 16-05-16 | Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel | RE |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 79 | 2004-01-31 | |
Margaret Madden
PRN | Corporate Officer/Principal | - | 2016-06-23 |
| General Counsel | 77 | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Margaret Madden
BRD | Director/Board Member | - | 2016-06-23 |
Bryan Supran
BRD | Director/Board Member | - | 2016-06-23 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.41% | -6.33% | +43.43% | +71.02% | 63.29B | |
| -0.15% | +3.11% | +10.29% | +72.56% | 54.89B | |
| +0.57% | +4.64% | +12.82% | +89.79% | 53.28B | |
| +0.37% | +4.67% | +27.03% | +52.07% | 45.81B | |
| -1.21% | +2.32% | +21.80% | +123.81% | 43.46B | |
| -0.37% | +5.07% | +249.91% | +918.74% | 40.23B | |
| +0.05% | +6.75% | +14.48% | +56.75% | 33.45B | |
| +1.19% | -5.84% | +27.86% | -0.65% | 23.7B | |
| -0.38% | +4.55% | +37.71% | +28.10% | 23.76B | |
| Average | +0.28% | +0.33% | +49.48% | +156.91% | 42.43B | |
| Weighted average by Cap. | +0.38% | +0.55% | +47.86% | +158.53% |
- Stock Market
- Stocks
- Stock
Select your edition
All financial news and data tailored to specific country editions
